ライフサイエンスコーパス: TLR9

1 to ligation of BCR and Toll-like receptor 9 (TLR9).

2 pattern recognition by Toll-like receptor 9 (TLR9).

3 FN-gamma via the nucleotide-sensing receptor TLR9.

4 the Toll-like receptors (TLRs) 3, TLR7, and TLR9.

5 gonists, including those for TLR2, TLR7, and TLR9.

6 blocking BAFF, type I interferon, or TLR7 to TLR9.

7 the recognition of foreign DNA by endosomal TLR9.

8 ephritis, opposite of the effect of deleting Tlr9.

9 ibution of TLR7 is masked by the presence of TLR9.

10 A), TLR4 (896A/G, 1196C/T, and 3266G/A), and TLR9 (-1237T/C, -1486T/C, 1174G/A, and 2848C/T) SNPs by

11 indings were a protective association of the TLR9 +2848 GG genotype and a risk-enhancing association

12 ion showed a trend toward protection for the TLR9 +2848 GG genotype.

13 mmune-sensing molecule Toll-like receptor 9 (TLR9)(4), and its interaction with beclin 1, in exercise

14 Lastly, we show that TLR9(471-1032) is also a dominant-negative regulator of

15 s to generate a mature form of the receptor (TLR9(471-1032)).

16 We show that TLR9(471-1032), corresponding to the proteolytically cle

17 TLR9 accumulates on the cell surface, where it recognize

18 nhibition of phagosomal acidification blocks TLR9 accumulation on phagosomes containing beta-1,3 gluc

19 TLR9 activation alleviates ILC2-driven AHR and airway in

20 We show that TLR9 activation by CpG A suppresses IL-33-mediated AHR a

21 plasma resulted in a substantial decrease in TLR9 activation capacity.

22 cellular compartments for the early steps of TLR9 activation in dendritic cells (DCs).

23 We sought to determine the role of TLR9 activation in regulating ILC2 function and to evalu

24 TLR9 activation occurs via its dimerization.

25 This research supports a potential role of TLR9 activation of an innate immune response evident in

26 N requires backbone phosphorothioate but not TLR9 activation to render and maintain endothelial stalk

27 ed NF-kappaB activation, IL-8 secretion, and TLR9 activation, but Cagbeta was dispensable for these r

28 ne pDCs did not express BCMA, not even after TLR9 activation.

29 thymic B cells using Epstein-Barr virus and TLR9 activation.

30 lexes potently amplify Toll-like receptor 9 (TLR9) activation in immune cells and exacerbate autoimmu

31 n into host cells, and Toll-like receptor 9 (TLR9) activation is attributed to delivery of bacterial

32 Here we provide evidence that TLR9 activity is significantly increased at time of dise

33 for CH) displayed an exaggerated response to TLR9 agonism, including worse splenomegaly and anemia.

34 H, have an enhanced inflammatory response to TLR9 agonism.

35 mmatory cytokines after stimulation with the TLR9 agonist CpG.

36 onists imiquimod and Sendai virus and to the TLR9 agonist CpG.

37 receptor (TLR) agonists in vivo In mice, the TLR9 agonist cytosine-phosphate-guanine (CpG) oligodeoxy

38 nd human B cells, BCR ligands that deliver a TLR9 agonist induce an initial proliferative burst that

39 ntraplantar and intrathecal injection of the TLR9 agonist ODN 1826 induced mechanical allodynia in bo

40 f whom participated in a clinical trial of a TLR9 agonist that included an analytical treatment inter

41 h enhanced innate signaling, we used TLR4 or TLR9 agonist treatment at the time of infection, which r

42 TLR9 agonist treatment in HIV infection has a dual poten

43 d, a TLR7 agonist) or bacterial (ODN 2395, a TLR9 agonist) surrogates.

44 alpha than wild-type mice after injection of TLR9 agonist, and BCAP promoted TLR7 and TLR9-induced IF

45 se model in which repeated treatments of the TLR9 agonist, ODN1826, was delivered to the mouse, we ob

46 tumoral injection of a highly interferogenic TLR9 agonist, SD-101, in anti-PD-1 nonresponders led to

47 (GBS) GBS67 protein antigen with the CpGODN TLR9 agonist.

48 ic antibodies or the CpGODN to function as a TLR9 agonist.

49 immunostimulatory CpG-A oligodeoxynucleotide TLR9 agonist.

50 lthough the well-known Toll like receptor 9 (TLR9) agonist CpGODN has shown promising results as vacc

51 ligand (CD40L) and the Toll-like receptor 9 (TLR9) agonist cytidine-phosphate-guanosine oligodeoxynuc

52 Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate.

53 drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could function as an enhancer of

54 ependently of TLR agonist used (i.e. TLR2 or TLR9 agonists).

55 ker responses were evident after exposure to TLR9 agonists, potentially due to very low expression of

56 In addition to TLR9 agonists, TLR2, TLR3, or TLR4 agonists, as well as

57 oduction are type I IFNs and TLR7, TLR8, and TLR9 agonists.

58 Toll-like receptor 9 (TLR9) agonists have gained traction in recent years as p

59 Of note, the expression of Tlr9, Aim2 and Tmem173, key DNA sensor genes, was marked

60 s triggered by Brucella abortus DNA involves TLR9, AIM2, and stimulator of IFN genes (STING).

61 te DNA-sensing through Toll-like receptor 9 (TLR9) along with inflammatory cytokine receptor IFN-gamm

62 rate that we can "knock in" this ability for TLR9 amplification in membrane-active AMP mutants, which

63 We demonstrate that TLR9 and CD82 associate in macrophages, which occurs in

64 bacteriophage levels exacerbated colitis via TLR9 and IFN-gamma.

65 Both TLR9 and its ligand, the dinucleotide CpG, were present

66 ytes in neonates that express high levels of TLR9 and low levels of TLR7, which may explain why TLR9

67 ATRA-treated cGVHD B cells had elevated TLR9 and PAX5, but not BLIMP1 (a gene-expression pattern

68 We demonstrate this crosstalk between TLR9 and PI3Kgamma in vitro using human PBMCs.

69 hese structures to their ability to activate TLR9 and show that a key criterion is the AMP's ability

70 ulating a model antigen ovalbumin along with TLR9 and STING ligands within liposomes, a well-establis

71 Whereas TLR9 and TLR3 are released from UNC93B1, TLR7 does not d

72 s detected by pattern-recognition receptors (TLR9 and TLR3) leading to a type-I IFN mediated innate i

73 This work revealed opposing effects of TLR9 and TLR3, TLR4, and TLR7 on the key angiogenic path

74 dual and a triple adjuvant combination, TLR4/TLR9 and TLR4/TLR7/TLR9, for further evaluation and foun

75 s resulting from inappropriate activation of TLR9 and TLR7.

76 foundation for the effect of anesthetics on TLR9 and will pave the way for future studies to determi

77 uch as endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) and cytoplasmic proteins (absent in melanoma 2 and

78 Toll-like receptor 9 (TLR9) and Phosphatidylinositol-3-kinase gamma (PI3Kgamma

79 propose that this mechanism integrating BCR, TLR9, and cytokine signals provides a peripheral checkpo

80 elationship among the B cell receptor (BCR), TLR9, and cytokine signals that regulate B cell response

81 TLR9, establish the cellular requirement for TLR9, and evaluate the role of obesity-induced changes i

82 Finally, our data have suggested that TLR2, TLR9, and Mal/TIRAP controlled differentially the emerge

83 cifically limits signalling of TLR7, but not TLR9, and prevents TLR7-dependent autoimmunity in mice.

84 inforces the compartmentalized activation of TLR9, and provides a mechanism by which activation of in

85 AC recognition receptors, low expression of TLR9, and reduced TLR responsiveness to nucleic acids.

86 voked mechanical allodynia was attenuated by TLR9 antagonism or Tlr9 mutation only in male mice.

87 Finally, TLR9 antagonism reduced paclitaxel-induced mechanical al

88 Propofol bound to the TLR9 antagonist binding site.

89 This effect was negated by either a TLR9 antagonist or DNase treatment.

90 Mice that lack TLR9 are deficient in both exercise-induced activation o

91 Both NO and TLR9 are important elements of innate immunity to mycoba

92 gulation that differentiate between TLR7 and TLR9 are unknown.

93 in CD4(+) T cells, NA-TLRs, TLR3, TLR8, and TLR9 are upregulated by FcgammaRIIIa-pSyk cosignaling an

94 lasma membrane and associated with disrupted TLR9 at the submembrane.

95 After engagement of TLR7/8 or TLR9, BCMA was detected also on the cell surface of pDCs

96 ibrutinib and promotes assembly of the MYD88-TLR9-BCR (My-T-BCR) supercomplex, which initiates prosur

97 TLR9 binds beclin 1, and this interaction is increased b

98 Ex vivo, TLR9(-/-) bone marrow-derived macrophages produced more

99 entation and crosspriming depend not only on TLR9, but also on interferon type I signaling, and both

100 ent of NASH in animal models requires intact TLR9, but how the TLR9 pathway is activated in NASH is n

101 imer (referred to herein as TLR1/2), TLR7 or TLR9, but not upon engagement of TLR3 or TLR4.

102 -alpha response to MHV68 in pDC are TLR7 and TLR9, but the contribution of TLR7 is masked by the pres

103 Given that TLR9 can respond to mitochondrial DNA, a danger signal t

104 d nanoparticles carrying a CpG DNA ligand of TLR9 can suppress tumor growth in several animal models

105 he Toll-like receptor (TLR) family, TLR7 and TLR9, can recognize self-RNA and self-DNA, respectively.

106 ocalized to the kidney more efficiently than Tlr9(-/-) CD4(+)CD25(+) cells.

107 ned the ex vivo dose effects mediated by the TLR9(+) cell populations (dendritic cells, macrophages,

108 endritic cells (pDC) to MHV68 was reduced in Tlr9 (-/-) cells compared to levels in wild type (WT) ce

109 in inflammatory models where DNA sensing via TLR9 contributes to disease, such as silicosis and drug-

110 Our data show that UNC93B-dependent TLR7 and TLR9 cooperate in and contribute to detection and contro

111 vestigated whether an N-terminal fragment of TLR9 could be responsible for regulation of the mature o

112 olyribocytidylic acid), TLR2 (Pam3CSK4), and TLR9 (CpG) remained comparable within the first 2 h.

113 Mer(-/-) mice with a global MyD88, TLR7, or TLR9 deficiency and cell type-specific MyD88 deficiency

114 Notably, Tlr9 deficiency in B cells was sufficient to exacerbate

115 guishing anti-nucleosome antibodies, whereas Tlr9 deficiency in dendritic cells (DCs), plasmacytoid D

116 Our studies show intestinal TLR9 deficiency results in exacerbated hepatic IR injury

117 Thus, B cell-specific Tlr9 deficiency unlinked disease from autoantibody produ

118 cted against hepatic IR injury in intestinal TLR9 deficient mice.

119 estinal apoptosis/inflammation in intestinal TLR9 deficient mice.

120 and apoptosis after hepatic IR in intestinal TLR9 deficient mice.

121 ins TLR9-dependent, as inhibition is lost in TLR9 deficient mice.

122 d propionate levels were lower in intestinal TLR9 deficient mice.

123 Toll-like receptor 9 (TLR9)-deficient (TLR9(-/-)) mice are resistant to period

124 Nevertheless, the corresponding TLR9-deficient autoimmune-prone strains consistently dev

125 upus erythematosus-disease is exacerbated in TLR9-deficient mice but attenuated in TLR7-deficient mic

126 TLR9-deficient mice responded significantly weaker to Id

127 r of UNC93B-deficient mice, in the spleen of TLR9-deficient mice, and in the liver and spleen of Tlr7

128 deficient in CD4(+)CD25(+) cells, and WT and TLR9-deficient Tregs had similar suppressive function ex

129 In addition, Dectin-1 regulates TLR9-dependent gene expression.

130 Moreover, CD82 is essential for TLR9-dependent myddosome formation in response to CpG st

131 Finally, CD82 modulates TLR9-dependent NF-kappaB nuclear translocation, which is

132 ther, histone-bound DNA stimulated endosomal Tlr9-dependent responses in a Clec2d-dependent manner.

133 Lastly, BMS-986126 inhibited TLR7- and TLR9-dependent responses using cells derived from lupus

134 ttenuation of angiogenesis, however, remains TLR9-dependent, as inhibition is lost in TLR9 deficient

135 Mice deficient in intestinal epithelial TLR9 develop small intestinal Paneth cell hyperplasia an

136 hat isoflurane and sevoflurane bound to both TLR9 dimer interface and 5'-xCx DNA binding site.

137 n Unc93b (-/-) pDC, as well as in Tlr7 (-/-) Tlr9 (-/-) double-knockout pDC, the IFN-alpha response t

138 mes, and use it to uncover unique aspects of TLR9-driven disease.

139 type I interferon (IFN) receptor signaling, TLR9-driven fatality is dependent on IFN-gamma receptor

140 ng SIRPalpha (SIRPalpha(-/-)) in mice during TLR9-driven inflammation exacerbates and accelerates the

141 Instead, TLR9-driven inflammation induced a Ccr2-independent expa

142 Importantly, IFN-gamma is essential for TLR9-driven suppression, and IFN-alpha cannot compensate

143 By inducing TLR9 dysregulation at different stages of life, we show

144 nd low levels of TLR7, which may explain why TLR9 dysregulation is particularly consequential early i

145 c autoinflammatory disease, dysregulation of TLR9 early in life drives a severe inflammatory disease

146 However, responses to TLR9 engagement are not uniform, but diametrically oppos

147 Toll-like receptor 9 (TLR9) enhances proinflammatory responses, but whether it

148 were to identify NASH-associated ligands for TLR9, establish the cellular requirement for TLR9, and e

149 of Ag-specific CD8 T cells was dependent on TLR9 expression on hematopoietic cells and partially dep

150 these to test cell type-specific effects of Tlr9 expression on the regulation of SLE pathogenesis.

151 question, we created 2 alleles to manipulate TLR9 expression, allowing for either selective deletion

152 djuvant combination, TLR4/TLR9 and TLR4/TLR7/TLR9, for further evaluation and found that both combina

153 a mechanism that prevents the activation of TLR9 from locations other than endosomes.

154 Preventing release of TLR9 from UNC93B1, either by mutations in UNC93B1 that i

155 ught to analyze whether CD19 is required for TLR9 function in human B cells.

156 jury, we examined the role of anesthetics on TLR9 function.

157 Moreover, TLR9 functions in a muscle-autonomous fashion in ex vivo

158 The rs352140-TT in the TLR9 gene proved to be associated with lower risk to sev

159 Mice lacking intestinal TLR9 had profoundly increased liver injury after hepatic

160 DNA binding to neutrophils' surface (s)TLR9 has been evidenced.

161 y, we tested whether mice lacking intestinal TLR9 have increased hepatic IR injury.

162 For example, TLR7 and TLR9 have opposing effects in mouse models of systemic l

163 We propose that synergistic TLR9/IFN-gammaR activation of T-bet(+) B cells is a mech

164 s, potentially due to very low expression of TLR9 in bdMphi.

165 either uptake of GFP-HSV nor localization of TLR9 in CD71(+) endosomes, directing us to investigate d

166 In this study, we examined the role of TLR9 in CIPN induced by paclitaxel in WT and Tlr9 mutant

167 mechanism that prevents hyper-activation of TLR9 in DCs.

168 the requirement for proteolytic cleavage of TLR9 in endosomes to generate a mature form of the recep

169 ypassing the compartmentalized activation of TLR9 in endosomes, and use it to uncover unique aspects

170 ion and depletion studies defined a role for TLR9 in maintaining Treg-mediated homeostasis in cisplat

171 ht the nonredundant role of B cell-expressed TLR9 in regulating lupus and suggest therapeutic potenti

172 d the pattern-recognition receptors TLR7 and TLR9 in the vascular wall, resulting in profound vascula

173 ion, as highlighted by Toll-like receptor 9 (TLR9) in the endosomal compartment and cyclic GMP-AMP sy

174 lator of vascular homeostasis, Fli1, whereas TLR9 increased Fli1 levels.

175 es in an FcgammaRIIA-dependent and TLR7- and TLR9-independent manner that likely contributes to local

176 CD19 is required for TLR9-induced B-cell activation.

177 rgy with prednisolone in assays of TLR7- and TLR9-induced IFN target gene expression using human PBMC

178 of TLR9 agonist, and BCAP promoted TLR7 and TLR9-induced IFN-alpha production specifically in pDC.

179 demonstrate the requirement of PI3Kgamma for TLR9-induced inflammation in a model of CpG-induced pleu

180 signal transduction events that occur during TLR9-induced IRF7 activation.

181 plement C3 was the dominant gene targeted by TLR9-induced NF-kappaB signaling in CAF.

182 demonstrate that ligation of TLR3, TLR4, and TLR9 induces murine DC production of complement componen

183 y individuals (n = 34) under T helper 1- and TLR9-inducing conditions.

184 id not preclude the precipitation of sHLH in TLR9-inflamed SIRPalpha(-/-) mice, whereas macrophage de

185 iency and fail to fully develop sHLH, albeit TLR9-inflamed wild-type and CD47(-/-) mice exhibited hem

186 omised by Tlr9 mutation or by treatment with TLR9 inhibitor only in male animals.

187 mechanisms and biological pathways by which TLR9 instigates periodontal inflammation are yet to be i

188 ma is required for immune responses in which TLR9 is a relevant trigger.

189 TLR9 is activated by sensing ligands in specific endosom

190 Toll-like receptor 9 (TLR9) is a regulator of disease pathogenesis in systemic

191 Toll-like receptor 9 (TLR9) is an endosome bound, innate immune receptor that

192 ed receptors, Toll-like receptor (TLR) 7 and TLR9, is balanced to allow recognition of microbial nucl

193 Activation of TLR9 leads to production of IFN-alpha, which drives IFN-

194 omodulatory microparticle containing natural TLR9 ligand (MIS416).

195 ng CpG ODN 2006, a synthetic oligonucleotide TLR9 ligand (TLR9L).

196 In contrast, the TLR9 ligand class C, ODN2395, increased angiogenesis.

197 coll), each containing >100 molecules of the TLR9 ligand, DV230.

198 tes uptake of CpG oligonucleotide ligands by TLR9 ligand.

199 ted the ability of the Toll-like receptor 9 (TLR9) ligand CpG to modulate established disease in the

200 Microparticle-based delivery of TLR9 ligands might serve as a therapeutic strategy for a

201 l guanosyl dinucleotide motifs (CpG ODN) are TLR9 ligands with attractive immunostimulatory propertie

202 l program, robust responsiveness to TLR7 and TLR9 ligands, and a propensity for IgG2a/c production.

203 nfiltration in the WT ligated but not in the TLR9(-/-) ligated mice compared to the unligated control

204 oderate or severe periodontitis; whereas the TLR9 marker was associated with lower chance to develop

205 in human PMNs through Toll-like receptor 9 (TLR9)-mediated release of neutrophil elastase and protei

206 r for IgE, followed by Toll-like receptor 9 (TLR9)-mediated sensing of DNA in phagosomes.

207 ted by nuclear translocation of IRF3 whereas TLR9-mediated activation occurs through IRF7.

208 P-70 appears to be of crucial importance for TLR9-mediated activation of Syk.

209 cGAS-STING pathway exists in parallel to the TLR9-mediated DNA recognition in human pDCs with cross-t

210 Collectively, these results uncover a TLR9-mediated endogenous mechanism that impairs PMN phag

211 DC prestimulation of cGAS-STING dampened the TLR9-mediated IFN production.

212 id crystalline immune complexes that amplify TLR9-mediated plasmacytoid dendritic cell (pDC)-hyperact

213 ce with the cell type-specific expression of TLR9, MGN1703 treatment led to pronounced activation of

214 e, and in the liver and spleen of Tlr7 (-/-) Tlr9 (-/-) mice.

215 model of periodontitis, we demonstrate that TLR9(-/-) mice exhibited significantly less alveolar bon

216 riodontitis, revealed reduced neutrophils in TLR9(-/-) mice on day 1 postinfection compared to the le

217 Tlr9(-/-) mice were not deficient in CD4(+)CD25(+) cells

218 y CD25(-) splenocytes from wild-type (WT) or Tlr9(-/-) mice, AKI was similarly enhanced.

219 The TMP-injected Tlr9(-/-) mice, and not the wild-type mice, also develop

220 Toll-like receptor 9 (TLR9)-deficient (TLR9(-/-)) mice are resistant to periodontitis, a diseas

221 We conclude that TLR9 modulates periodontal disease progression at both t

222 ative regulator of TLR signaling, in ligated TLR9(-/-) mouse gingival tissues compared to its express

223 pain sensitivity was not affected in either Tlr9 mutant male or female mice.

224 TLR9 in CIPN induced by paclitaxel in WT and Tlr9 mutant mice of both sexes.

225 f WT and Tlr4 KO mice but failed to do so in Tlr9 mutant mice.

226 sexes, but these changes were compromised by Tlr9 mutation in male animals.

227 lodynia was attenuated by TLR9 antagonism or Tlr9 mutation only in male mice.

228 ynia in both sexes, which was compromised by Tlr9 mutation or by treatment with TLR9 inhibitor only i

229 s, and this infiltration was not affected by Tlr9 mutation.

230 dy, we report that the Toll-like receptor 9 (TLR9)-MyD88 pattern-recognition receptor pathway is uniq

231 an unexpected, powerful inhibitory effect of TLR9 on MYD88(L265P) B-cell proliferation and differenti

232 tion receptors such as Toll-like receptor 9 (TLR9) on the endosomal surface of immune cells, in parti

233 ations in UNC93B1 that increase affinity for TLR9 or through an artificial tether that impairs releas

234 Critically, B cell-specific Tlr9 overexpression resulted in ameliorated nephritis, o

235 gene expression level of TLR2 (P = .02) and TLR9 (P = .02), a greater than 4-fold increase in IL-17A

236 luate the role of obesity-induced changes in TLR9 pathway activation.

237 mal models requires intact TLR9, but how the TLR9 pathway is activated in NASH is not clear.

238 immune response pathways in addition to the TLR9 pathway, which is mainly activated by the CpG motif

239 Moreover, the endosomal DNA sensor TLR9 promotes anti-dsDNA responses and SLE-like disease

240 conclusion, we identified a pathway by which TLR9 promotes renal Treg accumulation in AKI.

241 mulated cells activated the mTOR pathway via TLR9 receptor to induced MMP-7, beta-glucan-stimulated c

242 TLR9 recognizes unmethylated cytosine-phosphate-guanine

243 TLR9 regulates the assembly of the endolysosomal phospha

244 ovide a new perspective on the complexity of TLR9 regulation by proteolytic cleavage and offer potent

245 mation evoked by E. coli Genetic deletion of TLR9 renders mice unresponsive to CpG DNA.

246 Why TLR9 represses disease while TLR7 and MyD88 have the opp

247 , this study demonstrates that inappropriate TLR9 responses can drive a severe autoinflammatory disea

248 Moreover, VAS2870 blocked the TLR9/RP105-induced B cell activation and thereby all Ig

249 We revealed that TLR9/RP105-mediated stimulation of human B cells involve

250 endoplasmic reticulum stress response in the TLR9/RP105-stimulated cells was higher in IgG(+) than in

251 ese findings reveal sex-dimorphic macrophage TLR9 signaling in chemotherapy-induced neuropathic pain.

252 TLR9 signaling is specifically essential in pDCs but not

253 Understanding the regulation of the TLR9 signaling pathway and the involvement of A20 as a l

254 Here, we show that macrophage TLR9 signaling promotes CIPN in male mice only.

255 strates that CD82 is a specific regulator of TLR9 signaling, which may be critical in cancer immunoth

256 sion of Staphylococcus aureus is mediated by TLR9 signaling.

257 riggered NETosis is independent of classical TLR9 signaling.

258 consequently limiting protease activity and TLR9 signaling.

259 32) is also a dominant-negative regulator of TLR9 signaling.

260 naling and in a CSS mouse model dependent on TLR9 signaling.

261 ting Erk1/2 and p38 activation downstream of TLR9 signaling.

262 an innate immune adaptor for TLR7, TLR8 and TLR9 signalling, revealing a clear mechanistic analogy w

263 tial to treat diseases mediated by excessive TLR9 signalling.

264 ial in modulating and perhaps even enhancing TLR9 signals in B cells.

265 iptional signature, and they rely on TLR7 or TLR9 signals in the context of Th1 cytokines for their f

266 gG1(+) B cells are triggered by IFNgamma and TLR9 signals, likely contributing to enhanced CXCR3-medi

267 3a receptor and the fibroblastic knockout of TLR9 similarly resulted in immune suppression with a sig

268 mined the frequency of TLR2, TLR3, TLR4, and TLR9 single-nucleotide polymorphisms (SNPs) and investig

269 ndings uncover a mechanism by which TLR7 and TLR9 specify monocyte fate and identify a specialized po

270 nt viral loads, particularly from Tlr7 (-/-) Tlr9 (-/-) splenocytes compared to levels in the WT.

271 -/-), Tlr7 (-/-) Tlr9 (-/-), Tlr7 (-/-), and Tlr9 (-/-) splenocytes.

272 rapy, whereas clonal B cells unresponsive to TLR9 stimulation persist for at least 24 weeks, although

273 type I IFNs (IFN-I) in response to TLR7 and TLR9 stimulation, it is assumed that their main function

274 on and reduced IKKalpha phosphorylation upon TLR9 stimulation.

275 M levels were elevated upon ex vivo anti-BCR/TLR9 stimulation.

276 or (TACI), and CD23 activation markers after TLR9 stimulation.

277 ed lung fibroblasts to Toll-like receptor 9 (TLR9) stimulation by CpG-oligodeoxynucleotide (CpG-ODN)

278 significantly weaker to Id-3F7.A10 than did TLR9-sufficient mice, suggesting that the cognate BCR ef

279 type and a risk-enhancing association of the TLR9 TA haplotype with pustule formation; logistic regre

280 ll as expression of endosomal TLRs, TLR7 and TLR9, that modulate production of IFN.

281 We found that deleting TLR7 or TLR9, the receptors for RNA and DNA, had no effect on mo

282 tently infected WT, Unc93b (-/-), Tlr7 (-/-) Tlr9 (-/-), Tlr7 (-/-), and Tlr9 (-/-) splenocytes.

283 necessary for trafficking of TLR3, TLR7, and TLR9 to endosomes.

284 nopeptidase IRAP, the trafficking of CpG and TLR9 to lysosomes and signaling via TLR9 were enhanced i

285 c redistribution and accumulation of cleaved TLR9 to phagosomes.

286 of NF-kappaB-->ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemo

287 actor FHOD4, which slowed the trafficking of TLR9 toward lysosomes.

288 We report that CD82 is a key regulator of TLR9 trafficking and signaling.

289 n tyrosine kinase activation is required for TLR9 trafficking to beta-1,3 glucan-, A. fumigatus-, and

290 Additional TLR9 triggering further upregulated T-bet and CXCR3, and

291 Thus, endosomal retention of TLR9 via the interaction of IRAP with the actin cytoskel

292 CpG and TLR9 to lysosomes and signaling via TLR9 were enhanced in DCs and in mice following bacteria

293 t not TLR2 (-/-), TLR5 (-/-), TLR7 (-/-), or TLR9 (-/-), were more susceptible to P. aeruginosa adhes

294 complexes that trigger strong recognition by TLR9, which is conventionally known to bind single DNA l

295 B cells express the innate receptor, TLR9, which signals in response to unmethylated CpG sequ

296 In contrast to TLR9, which suppressed activation of the FOXO3A pathway,

297 nd initiated signaling through both TLR7 and TLR9, which was not utilized in the absence of Ab.

298 and sevoflurane increased the activation of TLR9, while propofol attenuated it.

299 Engaging TLR9 with CpG oligonucleotide contributes to the develop

300 (pDC) in response to engagement of TLR7 and TLR9 with endocytosed nucleic acids.